The Kaiser Family Foundation estimates that Aduhelm will inflict significant costs on Medicaid as it covers the Alzheimer’s treatment. In a July 13 report, the foundation claimed that with a 23.1 ...

Excellus BlueCross BlueShield joins the ranks of six Blue Cross Blue Shield affiliates who are refusing to cover Aduhelm, Biogen’s Alzehimer’s drug, without definite proof of its effectiveness.

WASHINGTON (AP) — The Food and Drug Administration (FDA) has approved new prescribing instructions that are likely to limit the use of a controversial new Alzheimer's drug. The update comes one month ...

The release by the U.S. CMS of the final national coverage determination (NCD) for Biogen Inc.’s Alzheimer disease (AD) drug, Aduhelm (aducanumab), lit speculation on the meaning for others in the ...

Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago. The drugmaker also said Wednesday that it will ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. The first new Alzheimer’s treatment in more ...

A month after approving a controversial new Alzheimer’s drug, U.S. health regulators on Thursday signed off on new prescribing instructions that are likely to limit its use. The Food and Drug ...